FcγR-profiles of alloimmunized women compared with healthy controls
| . | Controls (N = 199) (%) . | Alloimmunized . | ||
|---|---|---|---|---|
| All (N = 305) (%) . | Adequate Rh-Ig (N = 219) (%) . | No Rh-Ig (N = 86) (%) . | ||
| FCGR2A | ||||
| Allele frequency | ||||
| 131H* | 214 (53.5) | 316 (53.7) | 228 (52.1) | 88 (58.7) |
| 131R | 186 (46.5) | 272 (46.3) | 210 (47.9) | 62 (41.3) |
| Phenotype frequency | ||||
| At least 1 131H | 155 (77.9) | 236 (77.4) | 172 (78.5) | 64 (74.4) |
| No H | 44 (22.1) | 69 (22.6) | 47 (21.5) | 22 (25.6) |
| FCGR2B | ||||
| Allele frequency | ||||
| 232I† | 352 (88.4) | 541 (88.7) | 388 (88.6) | 153 (89.0) |
| 232T | 46 (11.6) | 69 (11.3) | 50 (11.4) | 19 (11.0) |
| 2B.1 GT | 727 (88.9) | 1058 (84.7) | 771 (85.6) | 287 (82.5) |
| 2B.4 CA‡ | 42 (5.1) | 93 (7.4)§ | 65 (7.2) | 28 (8.0) |
| Phenotype frequency | ||||
| 2B.4 | 38 (19.4) | 87 (28.5)§ | 63 (28.8)§ | 24 (27.9) |
| No 2B.4 | 161 (80.9) | 218 (71.5) | 156 (71.2) | 62 (72.1) |
| FCGR2C | ||||
| Haplotype frequency | ||||
| STOP | 363 (86.8) | 516 (80.9) | 375 (81.0) | 141 (80.6) |
| Classical-ORF¶ | 44 (10.5) | 100 (15.7)§ | 67 (14.5) | 33 (18.9)§,‖ |
| Nonclassical-ORF | 11 (2.6) | 22 (3.4) | 21 (4.5) | 1 (0.6)§,‖ |
| Phenotype frequency | ||||
| At least 1 Classical-ORF | 39 (19.6) | 91 (29.8)§ | 63 (28.8)§ | 28 (32.6)§ |
| No Classical-ORF | 160 (80.4) | 214 (70.2) | 156 (71.2) | 58 (67.4) |
| FCGR3A | ||||
| Allele frequency | ||||
| 158V# | 135 (32.8) | 229 (36.5) | 168 (37.3) | 61 (34.7) |
| 158F | 276 (67.2) | 398 (63.5) | 283 (62.7) | 115 (65.3) |
| Phenotype frequency | ||||
| At least 1 158V | 109 (54.8) | 182 (59.7) | 132 (60.3) | 50 (58.1) |
| No 158V | 90 (45.2) | 123 (40.3) | 87 (39.7) | 36 (41.9) |
| FCGR3B | ||||
| Haplotype frequency | ||||
| FCGR3B*01** | 164 (39.9) | 236 (37.6) | 172 (37.8) | 64 (37.2) |
| FCGR3B*02 | 237 (57.7) | 378 (60.3) | 272 (59.8) | 106 (61.6) |
| FCGR3B*03** | 10 (2.4) | 13 (2.1) | 11 (2.4) | 2 (1.2) |
| Phenotype frequency | ||||
| At least 1 FCGR3B*01 | 127 (63.8) | 188 (61.6) | 136 (62.1) | 52 (60.5) |
| No FCGR3B*01 | 72 (36.2) | 117 (38.4) | 83 (37.9) | 34 (39.5) |
| . | Controls (N = 199) (%) . | Alloimmunized . | ||
|---|---|---|---|---|
| All (N = 305) (%) . | Adequate Rh-Ig (N = 219) (%) . | No Rh-Ig (N = 86) (%) . | ||
| FCGR2A | ||||
| Allele frequency | ||||
| 131H* | 214 (53.5) | 316 (53.7) | 228 (52.1) | 88 (58.7) |
| 131R | 186 (46.5) | 272 (46.3) | 210 (47.9) | 62 (41.3) |
| Phenotype frequency | ||||
| At least 1 131H | 155 (77.9) | 236 (77.4) | 172 (78.5) | 64 (74.4) |
| No H | 44 (22.1) | 69 (22.6) | 47 (21.5) | 22 (25.6) |
| FCGR2B | ||||
| Allele frequency | ||||
| 232I† | 352 (88.4) | 541 (88.7) | 388 (88.6) | 153 (89.0) |
| 232T | 46 (11.6) | 69 (11.3) | 50 (11.4) | 19 (11.0) |
| 2B.1 GT | 727 (88.9) | 1058 (84.7) | 771 (85.6) | 287 (82.5) |
| 2B.4 CA‡ | 42 (5.1) | 93 (7.4)§ | 65 (7.2) | 28 (8.0) |
| Phenotype frequency | ||||
| 2B.4 | 38 (19.4) | 87 (28.5)§ | 63 (28.8)§ | 24 (27.9) |
| No 2B.4 | 161 (80.9) | 218 (71.5) | 156 (71.2) | 62 (72.1) |
| FCGR2C | ||||
| Haplotype frequency | ||||
| STOP | 363 (86.8) | 516 (80.9) | 375 (81.0) | 141 (80.6) |
| Classical-ORF¶ | 44 (10.5) | 100 (15.7)§ | 67 (14.5) | 33 (18.9)§,‖ |
| Nonclassical-ORF | 11 (2.6) | 22 (3.4) | 21 (4.5) | 1 (0.6)§,‖ |
| Phenotype frequency | ||||
| At least 1 Classical-ORF | 39 (19.6) | 91 (29.8)§ | 63 (28.8)§ | 28 (32.6)§ |
| No Classical-ORF | 160 (80.4) | 214 (70.2) | 156 (71.2) | 58 (67.4) |
| FCGR3A | ||||
| Allele frequency | ||||
| 158V# | 135 (32.8) | 229 (36.5) | 168 (37.3) | 61 (34.7) |
| 158F | 276 (67.2) | 398 (63.5) | 283 (62.7) | 115 (65.3) |
| Phenotype frequency | ||||
| At least 1 158V | 109 (54.8) | 182 (59.7) | 132 (60.3) | 50 (58.1) |
| No 158V | 90 (45.2) | 123 (40.3) | 87 (39.7) | 36 (41.9) |
| FCGR3B | ||||
| Haplotype frequency | ||||
| FCGR3B*01** | 164 (39.9) | 236 (37.6) | 172 (37.8) | 64 (37.2) |
| FCGR3B*02 | 237 (57.7) | 378 (60.3) | 272 (59.8) | 106 (61.6) |
| FCGR3B*03** | 10 (2.4) | 13 (2.1) | 11 (2.4) | 2 (1.2) |
| Phenotype frequency | ||||
| At least 1 FCGR3B*01 | 127 (63.8) | 188 (61.6) | 136 (62.1) | 52 (60.5) |
| No FCGR3B*01 | 72 (36.2) | 117 (38.4) | 83 (37.9) | 34 (39.5) |
Significance levels are indicated by symbols.
Increased affinity IgG1.
Increased inhibition of FcγRI signals.
Increased FcγRIIb expression.
Significant (P < .05) compared with controls.
Significant (P < .05) when the adequate prophylaxis group was compared with the group that had not received anti-D.
FcγRIIc expression.
Increased affinity to all IgG.
Increased affinity IgG3.